TechNavio's analysts forecast the Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market to grow at a CAGR of 3 percent over the period 2012–2016. One of the key factors contributing to this market growth is the increase in prevalence of the MRSA infection. The Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market has also been witnessing the increase in Governmental/Non-Governmental awareness programs. However, the increasing generic competition could pose a challenge to the growth of this market.
TechNavio's report, the Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market 2012–2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are Pfizer Inc., Cubist Pharmaceuticals Inc., ViroPharma Inc., Theravance Inc. and Forest Laboratories Inc.
The other vendors mentioned in the report are Basilea Pharmaceutica Ltd., Durata Therapeutics, Inc., Novartis AG, Trius Therapeutics, Inc., AstraZeneca plc., and GlaxoSmithKline plc.
Key questions answered in this report:
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
1. Executive Summary
2. List of Abbreviations
4. Market Research Methodology
4.1. Market Research Process
4.2. Research Design
4.3. Research Methodology
5. Scope of the Report
5.1. Market Overview
5.2. Product Offerings
6. Market Landscape
6.1. Global Cephalosporin Drugs Market
6.1.1. Market Size and Forecast
7. Five Force Analysis
8. Geographical Segmentation
9. Vendor Landscape
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Key Vendor Analysis
16.1. Pfizer Inc.
16.1.1. Business Overview
16.1.2. Key Information
16.1.3. SWOT Analysis
16.2. Cubist Pharmaceuticals Inc.
16.2.1. Business Overview
16.2.2. Key Information
16.2.3. SWOT Analysis
16.3. ViroPharma Inc.
16.3.1. Business Overview
16.3.2. Key Information
16.3.3. SWOT Analysis
16.4. Forest Laboratories Inc.
16.4.1. Business Overview
16.4.2. Key Information
16.4.3. SWOT Analysis
16.5. Theravance Inc.
16.5.1. Business Overview
16.5.2. Key Information
16.5.3. SWOT Analysis
17. Other Reports in this Series
List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Global Methicillin-resistant Staphylococcus aureus (MRSA) Drugs 2012-2016 (US$ millions)
Exhibit 3: Global Methicillin-resistant Staphylococcus aureus (MRSA) Drugs Market by Geographical Segmentation 2012
Exhibit 4: Global Methicillin-resistant Staphylococcus aureus (MRSA) Drugs Market by Vendor Segmentation 2012